PXDN as a pan-cancer biomarker and promotes tumor progress via immune inhibition in nasopharyngeal carcinoma
We characterized PXDN as a valuable biomarker for pan-cancer diagnosis and prognosis. We also uncovered new oncogenic roles for PXDN in promoting cancer progression and regulating T-cell immunosuppressive function in NPC.
Authors
- Yuchun Li (ORCID: https://orcid.org/0000-0001-5508-4721)
- Xueyan Ye (ORCID: https://orcid.org/0000-0002-2254-6165)
- Jian-Mei Lin
- Shi-Bing Li
- Yanhong Xiao (ORCID: https://orcid.org/0000-0003-0469-9392)
- Siyu Xiao (ORCID: https://orcid.org/0000-0001-7038-9531)
- Yuan Li (ORCID: https://orcid.org/0000-0003-3935-7237)
- Shu-Tao Cai
- Cui-Lan Zeng
- Fei-Xiong Chen
- Xu-Fa Yu
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3389/fonc.2024.1463011
- Citations
- 3
- Primary Topic
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.72